G&S Capital LLC grew its position in AbbVie Inc (NYSE:ABBV) by 2,963.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,103 shares of the company’s stock after buying an additional 35,892 shares during the quarter. AbbVie accounts for 2.4% of G&S Capital LLC’s holdings, making the stock its 16th largest holding. G&S Capital LLC’s holdings in AbbVie were worth $3,509,000 at the end of the most recent quarter.
Several other hedge funds have also recently modified their holdings of ABBV. Good Life Advisors LLC raised its stake in AbbVie by 5.6% in the second quarter. Good Life Advisors LLC now owns 10,060 shares of the company’s stock valued at $933,000 after buying an additional 537 shares during the last quarter. Lido Advisors LLC raised its stake in AbbVie by 2.4% in the second quarter. Lido Advisors LLC now owns 23,371 shares of the company’s stock valued at $2,165,000 after buying an additional 537 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its stake in AbbVie by 1.0% in the second quarter. Thompson Siegel & Walmsley LLC now owns 56,086 shares of the company’s stock valued at $5,196,000 after buying an additional 550 shares during the last quarter. Investors Asset Management of Georgia Inc. GA ADV raised its stake in AbbVie by 5.6% in the second quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 10,631 shares of the company’s stock valued at $985,000 after buying an additional 564 shares during the last quarter. Finally, Windsor Capital Management LLC raised its stake in AbbVie by 5.4% in the second quarter. Windsor Capital Management LLC now owns 11,122 shares of the company’s stock valued at $1,030,000 after buying an additional 565 shares during the last quarter. Institutional investors and hedge funds own 69.85% of the company’s stock.
A number of equities research analysts have commented on ABBV shares. SunTrust Banks decreased their price target on AbbVie from $157.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, October 22nd. Credit Suisse Group set a $85.00 price target on AbbVie and gave the company a “sell” rating in a research note on Saturday, October 20th. Wolfe Research initiated coverage on AbbVie in a report on Tuesday, October 23rd. They issued an “underperform” rating on the stock. Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $105.00 price objective on the stock in a report on Monday, October 1st. Finally, Bank of America cut their price objective on AbbVie from $107.00 to $106.00 and set a “buy” rating on the stock in a report on Thursday, October 4th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. AbbVie presently has an average rating of “Hold” and an average target price of $103.68.
In related news, EVP Henry O. Gosebruch sold 42,450 shares of the firm’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $90.10, for a total transaction of $3,824,745.00. Following the sale, the executive vice president now directly owns 30,350 shares of the company’s stock, valued at $2,734,535. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Laura J. Schumacher sold 94,140 shares of the firm’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $93.58, for a total value of $8,809,621.20. Following the sale, the insider now directly owns 192,398 shares in the company, valued at $18,004,604.84. The disclosure for this sale can be found here. 0.07% of the stock is owned by company insiders.
Shares of ABBV stock opened at $86.96 on Friday. The company has a current ratio of 1.20, a quick ratio of 1.08 and a debt-to-equity ratio of 8.70. The stock has a market capitalization of $136.21 billion, a PE ratio of 15.53, a PEG ratio of 0.84 and a beta of 1.68. AbbVie Inc has a fifty-two week low of $77.50 and a fifty-two week high of $125.86.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, November 2nd. The company reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.13. The business had revenue of $8.24 billion for the quarter, compared to analyst estimates of $8.23 billion. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The company’s revenue was up 17.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.41 earnings per share. Research analysts anticipate that AbbVie Inc will post 7.93 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be issued a dividend of $1.07 per share. This represents a $4.28 annualized dividend and a yield of 4.92%. This is a positive change from AbbVie’s previous quarterly dividend of $0.96. The ex-dividend date of this dividend is Monday, January 14th. AbbVie’s dividend payout ratio (DPR) is 68.57%.
COPYRIGHT VIOLATION NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/12/08/gs-capital-llc-raises-holdings-in-abbvie-inc-abbv.html.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
See Also: Trading Penny Stocks
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.